source
- Roche commits $750 million to double Oregon plant capacity as obesity drug push growsRoche's Genentech announced a $750 million investment to enlarge its device fill-finish facility in Hillsboro, Oregon. The expansion will double the plant's size and add end-to-end capabilities fo…
- Gray‑market copies of Lilly’s obesity drug retatrutide show weaker weight‑loss results, study findsA recent study examined the effectiveness of gray‑market versions of Eli Lilly’s triple‑agonist obesity drug retatrutide. The analysis found that patients using these unapproved copies experienced…